Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 6Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1

Conditions

Leukemia, Plasma Cell 1

Interventions

Dexamethasone 136Lenalidomide 79daratumumab 77Bortezomib 66pomalidomide 48Cyclophosphamide 48carfilzomib 43Calcium Dobesilate 42Specimen Handling 35Biopsy 32Magnetic Resonance Spectroscopy 29belantamab mafodotin 26fludarabine 23isatuximab 22iberdomide 19dexamethasone acetate 19dexamethasone 21-phosphate 19auricularum 19Melphalan 18talquetamab 17fludarabine phosphate 14elotuzumab 12selinexor 11X-Rays 10tocilizumab 9Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Crizotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Plasma cell × 90 days × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡